

HR 9358

Access to Innovative Treatments Act of 2022

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Nov 29, 2022

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Nov 30, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/9358>

Sponsor

Name: Rep. Barragan, Nanette Diaz [D-CA-44]

Party: Democratic • **State:** CA • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Joyce, John [R-PA-13]	R · PA		Nov 29, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Nov 30, 2022
Ways and Means Committee	House	Referred To	Nov 29, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Nov 29, 2022)

Access to Innovative Treatments Act of 2022

This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so. (Under the bill, adverse national coverage determinations are denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration.) The bill's requirements do not apply if the CMS already conducted such a review within a two-year period.

The bill also prohibits the CMS from applying prior coverage determinations that were made for drugs before they were approved by the FDA if such determinations are inconsistent with the drug's approval.

Actions Timeline

- **Nov 30, 2022:** Referred to the Subcommittee on Health.
- **Nov 29, 2022:** Introduced in House
- **Nov 29, 2022:** Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.